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ABSTRACT 
Neuroendocrine tumors of the rectum were regarded as benign, when 
Oberndorfer originally described the entity in 1907. Later, he acknowledged 
that some neuroendocrine tumors (or carcinoids, the term at that time) 
behave in a more aggressive manner, and a few of them even had the 
potential to metastasize with poor outcome. In the novel World Health 
Organization (WHO) classification launched in 2010, all neuroendocrine 
tumors of the gastrointestinal (GI) tract are malignant. In this classification, 
tumors of every part of the GI tract are graded uniformly according to 
proliferation index and mitotic frequency, whereas the TNM-classification 
(tumor, node, metastasis) is specific for each site.  Around 10% of 
gastroenteropancreatic neuroendocrine tumors (GEP-NETs) occur in the 
rectum. The prognostic accuracy of the WHO 2010 classification has been 
sufficiently validated in the stomach and pancreas, but in the rest of the GI 
tract, including the rectum, its prognostic value is inadequately confirmed. 
What would be useful, if possible, would be to reliably stratify rectal NETs 
into categories based on their metastatic potential. 
 The tumor series comprised 73 rectal NETs, with the main 
objective being to study the prognostic value of the WHO 2010 classification 
in rectal NETs: additionally, as the WHO classification has been used for a 
rather short time, tumor markers were tested to find a good, reliable 
prognostic tool.  
 The WHO 2010 had excellent prognostic significance; none of 
the G1-NETs (grade 1) metastasized, whereas G2-NETs were often 
disseminated, some of them at initial presentation. Metastatic NETs have a 
poor prognosis. Cell-cycle antigen cyclin A also correlated with prognosis, 
and G2-NETs with high cyclin A expression were all metastatic. 
Transcription factor prospero homeobox 1 (PROX1) was 
immunohistochemically positive in a significant proportion of rectal NETs, 
and showed a correlation with metastatic potential and survival. It was also 
possible to conclude that the novel stem cell-associated factor HES77 
(human embryonic stem cell factor 77) correlated well with rectal NETs 
metastatic potential and prognosis. 
 These results support the validity of the WHO 2010 classification 
in rectal NETs. In view of this study, for patients with a rectal G1-NET, one 
follow-up endoscopy to exclude local recurrence might suffice. Intensive 
follow-up does not seem indicated, as metastatic potential is very low. As to 
G2-NETs, a thorough work-up is recommended, since most of these tumors 
disseminate eventually, some after several years, and a standard 5-year 
follow-up may not suffice. In selected cases, adjuvant therapy even in the 
absence of metastatic lesions might be beneficial, although this was not the 
target of the study. PROX1-positivity suggests that colorectal 
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adenocarcinoma and rectal NET may, to some extent, share the same 
pathway in oncogenesis; this could lead to future therapeutic applications.  
The Ki-67 plays an established role as a prognostic marker in epithelial, 
hematolymphoid, and mesenchymal neoplasms, but its accuracy ought to be 
assessed separately in each tumor subtype. Furthermore, a selection of cell-
cycle antigens may have enhanced prognostic value:  the conclusion of this 
study was that cyclin A in combination with Ki-67 can recognize tumors with 
the highest propensity to metastasize. 
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INTRODUCTION 
The study of neuroendocrine tumors (NETs) has been challenging due to 
their rarity: it is time-consuming to collect materials with sufficient number 
of cases in order to validate new classifications and diagnostic markers. 
Moreover, very long follow-up periods are necessary, since these tumors are 
known to metastasize even very late; this makes the task even harder. After 
the introduction of the “carcinoid” entity by Oberndorfer in his famous 1907 
article, these tumors were considered altogether benign, or at least with 
much better prognosis than for conventional adenocarcinomas. Data 
accumulated, however, suggesting that some of these benign-appearing 
tumors had the ability to metastasize. For a long time, it remained unclear 
which tumors had this potential. 
 The nomenclature has undergone significant changes: the term 
“carcinoid” is no longer recommended due to its benign connotation. In 
certain countries, the term is still widely used in clinical practice, but in 
Europe, the recommended term “neuroendocrine tumor” has been 
extensively adopted by clinicians and pathologists. The old term frequently 
appears in research articles from both the old and new continents and Asia, 
however.  
 The present World health Organization (WHO) classification for 
neuroendocrine tumors of the gastrointestinal (GI) tract was launched in 
2010 (Bosman et al. 2010). It most certainly will be replaced in the future, 
like all tumor classifications eventually, when enough information allows the 
field to discard the previous classification. In the WHO 2010 classification, 
all GI – NETs are considered malignant. 
 As said, neuroendocrine tumors are rare; in Finland, around 200 
new gastroenteropancreatic (GEP) NETs are diagnosed annually, and of 
these, 20 (10%) occur in the rectum (unpublished data). Understandably, it 
has been difficult to gain vast experience in diagnostics or treatment of these 
patients in Finland because of its very small number of cases. In this study 
what became evident was that treatment and especially follow-up of these 
patients had been conducted in very many different ways, because national 
(and international), cohesive guidelines were lacking. The situation improved 
markedly after introduction of European and Nordic guidelines for their 
treatment and diagnosis (Caplin et al. 2012a, Janson et al. 2014). 
 In the novel WHO 2010 classification, the primary site of the 
tumor does not affect its grading, whereas there do exist specific TMN 
classifications (tumor, nodes, metastasis) for each anatomic region of the GI 
tract. When the classification was launched, evidence was sufficient to 
support the accuracy of the grading system mainly in NETs of the stomach 
and pancreas. In other parts of the GI tract, data were very limited, with 
additional reports needed to validate this classification’s prognostic value 
Introduction 
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(Bosman et al. 2010). In this work, the intention was discovery of how well 
the WHO 2010 classification correlated with survival.  
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REVIEW OF THE LITERATURE 
 
 
NEUROENDOCRINE SYSTEM OF THE GI TRACT  
HISTORICAL ASPECTS 
Neuroendocrine cells were discovered in 1897 by Kulchitsky. These cells were 
found to interact with chromium salts and thus carried the name 
enterochromaffin cell or Kulchitsky cell. In the first half of the twentieth 
century, the endocrine nature of these cells was revealed (Rindi et al. 2004). 
The endocrine capacity of the bowel was reported by Bayliss and Starling in 
1902. In 1917, Myerson discovered, in the nerve cells, intracytoplasmic 
argyrophilic granules staining positive with a silver stain. This was most 
likely the first report of neurosecretory granules, although the exact nature of 
the granules was elucidated later. In neuroendocrine cells, Masson-Fontana 
stain could demonstrate the positive argentaffin reaction, meaning that 
neuroendocrine cells are capable of taking up silver and reducing it to a 
visible metallic state. For this purpose, Masson-Fontana staining has largely 
been replaced by immunohistochemistry, but it is still in use in clinical 
pathology to demonstrate the presence of melanin pigment in tissues. The 
Grimelius stain was another silver stain for identifying argyrophilic 
neuroendocrine cells. The exact chemical reaction on which this staining is 
based remains unclear (Grimelius 1968). 
 
FUNCTIONING OF THE NEUROENDOCRINE SYSTEM AND CELL TYPES 
The epithelium of the rectum and colon contains four main cell types: 
enterocytes, Paneth cells, goblet cells, and neuroendocrine cells. It was first 
thought that neuroendocrine cells were derived from the neural crest, but 
eventually they proved to be of endodermal origin (Pictet et al. 1976). 
Neuroendocrine cells occur in almost every organ of the human body, but 
particularly in the GI tract, lung, and skin. In the GI tract they occur as 
scattered single cells, with the exception of the pancreas, where 
neuroendocrine cells form islets, as first described by Langerhans in 1869. In 
the small intestine, colon and rectum, neuroendocrine cells reside in the 
crypts of Lieberkühn, 5 to 10 neuroendocrine cells per crypt. The term 
“neuroendocrine” refers to their having features of both neural and 
endocrine cells (Wiedenmann et al. 1998). In the intestine and stomach these 
Review of the literature 
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cells are also called enteroendocrine cells. Neuroendocrine cells can produce, 
store, and, upon stimulation, release hormones. Two kinds of secretory 
vesicles exist: large dense-core vesicles (LDCV) and synaptic-like 
microvesicles (SLMV) (Wiedenmann et al. 1998). Synaptophysin and 
chromogranins are integral constituents of those vesicles. 
Defined by their hormonal products, 15 types of neuroendocrine cells are 
identifiable in the GI tract and pancreas (Rindi & Kloppel 2004); their 
distribution and frequency is site-specific: the rectum and colon harbor 
mainly serotonin-producing EC-cells and L-cells that produce glucagon-like 
immunoreactants (GLI) and pancreatic polypeptide-like peptide (PYY). 
Somatostatin-producing D-cells are very few in number in the colon and 
rectum (Solcia, Capella & Fiocca 1998). Other parts of the GI tract have a 
completely different distribution of neuroendocrine cells. The number of 
different cell types might be one explanation why NETs of the GI tract are a 
rather heterogeneous group, since a specific subtype of neuroendocrine cell is 
thought to give rise to a specific type of tumor (Kloppel 2011). 
Neuroendocrine cells form the diffuse endocrine system (DES) that plays 
an important role in regulating GI tract function by secreting hormones into 
the bloodstream, and also by exerting local control on gut motility, and 
controlling secretion and proliferation of mucosal cells (Solcia, Capella & 
Fiocca 1998). The first to propose the concept of a diffuse endocrine gland 
was Masson in 1928, and the idea was further developed by Feyrther in 
publications in 1938 and 1956. 
 
DIFFERENTIATION OF NEUROENDOCRINE CELLS 
Pluripotent stem cells are the precursor for enterocyte stem cells and 
secretory stem cells, from which Paneth cells, goblet cells, and 
neuroendocrine cells are derived (Yang et al. 2001, Jenny et al. 2002).  This 
is controlled by transcription factors such as caudal type homeobox 2 
(CDX2), mouse atonal homolog 1 (Math1), neurogenin 3 (Ngn3), NeuroD and 
prospero homeobox 1 (PROX1) (Silberg et al. 2000, Yang et al. 2001, Beck 
2002, Petrova et al. 2008). As a result of Notch signaling, in normal 
epithelium, two neuroendocrine cells are never adjacent (Apelqvist et al. 
1999, Jensen et al. 2000). The neuroendocrine system is capable of 
responding to different stimuli and of adapting its function accordingly 
(Karam & Leblond 1995). For example, chronic inflammation, as in chronic 
inflammatory bowel diseases, causes an increase in number of 
neuroendocrine cells (Miller & Sumner 1982, Gledhill, Enticott & Howe 1986, 
Bishop et al. 1987). This is achieved, probably not by proliferation of 
terminally differentiated neuroendocrine cells, but by entry of stem cells into 
the differentiation trail (Barrett et al. 1995). 
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NEUROENDOCRINE TUMORS 
HISTORY OF NETS 
The German pathologist Siegfried Oberndorfer (1876-1944) was the first to 
describe carcinoid tumors in 1907. He had encountered several cases in 
which this tumor had some features in common with adenocarcinoma, but 
found also differences in the growth pattern and, importantly, in its clinical 
behavior and prognosis, since none of the patients had any symptoms. 
Oberndorfer inferred that he had discovered a new tumor subtype, and also 
gave this tumor entity its name, which, although a bit obsolete today, still 
sometimes appears. Oberndorfer concluded that these new tumors, although 
resembling carcinomas, showed major differences. Hence the name in 
German: “karzinoide,” carcinoma-like. In his famous article he stated that 
these tumors are small, often multiple, do not infiltrate into surrounding 
tissues, have no metastatic potential, and are slow-growing and harmless 
(Oberndorfer 1907). He later admitted, when cases with metastases came to 
his knowledge that “malignant carcinoids” exist (Oberndorfer 1929). 
In 1929 Masson published his observations on appendiceal carcinoids; the 
series consisted of 50 tumors. He described very precise morphological 
details of tumor cells and discovered cytoplasmic vacuoles and granules 
absent from conventional adenocarcinomas. He also detected similarities 
between carcinoid tumor cells and cells of the adrenal cortex. In silver stains, 
Kulchitsky cells, and carcinoid tumor cells had common features: he 
concluded that both were of endocrine nature, and that Kulchitsky cells or 
enterochromaffin cells constitute a diffuse endocrine gland (Masson 1928). 
These observations have withstood the test of time and are still valid. 
Moreover, he postulated that intraneural argentaffin cells are the cells of 
origin in carcinoids. In the earliest articles on carcinoids, these novel tumors 
were thought to have a benign clinical course, but over time, metastatic cases 
with poor outcome were reported, raising doubts as to whether this was an 
entirely benign entity, after all.  
The earliest reports of NETs, or carcinoids as they were called at that 
time, concerned mainly lesions of the small bowel and appendix, and NETs 
were treated more or less as a homogeneous group; not much emphasis was 
placed on tumor localization. Later, the primary site of the tumor began to 
attract interest, and articles appeared taking this aspect into consideration.  
The first report on rectal carcinoid was by Saltykow in 1912. Stout 
reported a series of six rectal carcinoids in 1942. None of them showed 
metastases. He observed morphological differences and weaker positivity in 
silver staining compared to that of carcinoids at other sites, concluding that 
in these rectal carcinoids, the cell of origin was a pre-enterochrome cell of the 
rectal mucosa, where argentaffin (secretory) granules had not yet been 
formed (Stout 1942). Due to abnormal silver-staining properties of some 
rectal carcinoids, the term “atypical carcinoid” was introduced by Morson in 
Review of the literature 
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1958. At that time, this term did not refer to the potentially malignant nature 
of a tumor. This term was re-adopted later with the connotation of 
potentially malignant tumor behavior. In 1948, Pearson reported three rectal 
carcinoids, two with metastases (Pearson & Fitzgerald 1948). Prior to this, 29 
rectal carcinoids were reported in the literature, but only 2 of these were 
associated with distant metastases. Thus, up to that time, 32 rectal carcinoids 
had received mention in the literature, of these, 4 with distant metastases. It 
became evident that not all rectal carcinoids behave in an indolent manner, 
and some tumors have the potential to metastasize. It was unclear which 
features would predict poor outcome, however. Cruickshank and 
Cunningham had, in 1949, observed in their series of 17 carcinoids that the 
number of mitotic figures varied between tumors; they thought that tumors 
with increased mitoses indicated rapid growth, but they did not speculate on 
increased metastatic potential. Around the same time, Haynes and Pearson 
estimated that the rate of malignancy in rectal carcinoid is 12% (Pearson & 
Fitzgerald 1949, Haynes, Shirley & Hume 1953). Raven stated in his review 
article in 1950 that the occurrence of metastatic lesions in patients with a 
rectal carcinoid is only “a matter of time.” Nevertheless, he considered the 
risk smaller than in rectal adenocarcinomas. It is notable that by that time, 
no author had made an attempt to distinguish indolent cases from more 
aggressive ones prone to metastasize. Johnson et al reported in 1983 that 
certain growth patterns are associated with more aggressive behavior, the 
undifferentiated pattern being the worst. In the context of GI-tract tumors, 
the terms “neuroendocrine tumor” and “neuroendocrine carcinoma” 
appeared in the literature in the late 1980s. 
 
CLASSIFICATION OF GI – NETS 
The classification, terminology, and perception of NETs as a tumor entity 
have undergone considerable changes over the past years, causing confusion. 
After introduction of the carcinoid entity by Oberndorfer, these tumors were 
considered benign when compared to conventional adenocarcinomas. Quite 
soon, information and experience accumulated suggesting that some 
carcinoids failed to behave in an indolent manner after all. Tumors were 
divided into benign and malignant. In the latest WHO 2010 classification, all 
NETs are considered potentially malignant.  It is necessary that all health-
care providers adopt and implement the latest WHO 2010 classification and 
the terminology therein. All pathology reports must contain the essential 
information needed by clinicians to determine the accurate treatment for 
each patient. 
 
 21 
ERA OF THE CARCINOID TUMOR 
When Oberndorfer described the carcinoid entity in 1907, he considered 
carcinoid a benign tumor. Later, it became evident that some carcinoids do 
metastasize and are clearly malignant with poor prognosis. Even with the 
potential to metastasize acknowledged, the prognosis seemed better than in 
conventional GI tract adenocarcinomas. 
In 1961, Williams and Sandler classified GI - NETs according to their 
primary site: tumors were divided into carcinoids of the foregut (respiratory 
tract, thymus, and stomach), midgut (small intestine, appendix, and 
proximal colon) and hindgut (distal colon, and the rectum). Some 
morphological features characteristic of each region were observable, but this 
classification failed to predict patients’ clinical outcome and had little 
prognostic value (Williams & Sandler 1963).  
Subsequently, carcinoids were divided into typical and atypical (In early 
reports, the term “atypical carcinoid” referred to cases in which the silver 
staining was only weakly positive or negative in a tumor that was 
morphologically an obvious carcinoid). This classification was hardly clear-
cut: carcinoids with cellular atypia, elevated mitotic count, poorer 
differentiation, or focal necrosis received the diagnosis of atypical carcinoids. 
Few reports exist on whether this classification correlated with metastatic 
potential or prognosis. A study by Soga classified 156 pancreatic carcinoids: 
144 were typical carcinoids and 12 atypical carcinoids; this classification did 
not predict clinical outcome (Soga 2005a). Small-cell carcinoma of the lung 
is an old entity, but as to the GI tract, a report of an oat-cell carcinoma 
(small-cell carcinoma) in the esophagus appeared in 1952 (McKeown 1952) 
and in the pancreas in 1971, with oat-cell carcinoma regarded as a poorly 
differentiated carcinoid arising from the endocrine cells (Corrin et al. 1971).  
In the lung, the term “carcinoid” is still valid and commonly used, and 
“carcinoid syndrome” is an appropriate term. In the appendix, a special 
subtype of NET with both endocrine and exocrine function is called goblet 
cell carcinoid (Bosman et al. 2010), but otherwise in the GI tract, the term 
“carcinoid” is becoming obsolete; its use thus should probably be 
discouraged, not least because of its erroneous association with benign 
behavior. 
 
WHO 1980 AND WHO 2000 CLASSIFICATIONS 
In the first WHO classification of endocrine tumors in 1980, the term 
carcinoid applied to most endocrine tumors: carcinoids were tumors of the 
diffuse neuroendocrine system, ones either benign or being neoplasms with a 
better prognosis than carcinomas. These comprised enterochromaffin, 
gastrin and unspecific carcinoids. Neuroendocrine tumors of the pancreas 
and thyroid, small-cell carcinoma of the lungs and skin (Merkel cell 
carcinoma), and paragangliomas were excluded from the carcinoid group. 
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In 2000, the WHO launched the second classification for endocrine 
tumors (Solcia, Klöppel & Sobin 2000) with a significant change in 
terminology, with the terms “neuroendocrine tumor” and “neuroendocrine 
carcinoma” encouraged, instead of “carcinoid,” which served as a synonym 
for a well-differentiated neuroendocrine tumor. The WHO 2000 
classification for tumors of the gastrointestinal tract referred to this 
classification, when covering neuroendocrine tumors of the GI tract 
(Hamilton & Aaltonen 2000). The term “carcinoid” was, however, not 
entirely abandoned as yet. Well-differentiated neuroendocrine tumors were 
usually small (≤ 1cm) and considered benign. Tumors that were 1 to 2 cm in 
diameter or showed angioinvasion were thought to exhibit uncertain 
malignant potential.  Well-differentiated neuroendocrine carcinomas 
(malignant carcinoids) showed invasion of the muscularis propria or had 
metastasized and were thus considered of low-grade malignancy.  Poorly 
differentiated neuroendocrine carcinomas were high-grade malignancies 
with poor prognosis. The proliferation index and mitotic count were regarded 
as prognostic factors and were not actually included in the WHO 2000 
classification (Kloppel et al. 2007). 
 
 
 
 
WHO 2010 CLASSIFICATION 
The present classification for GI-NETs was launched in 2010. It includes 
grading for NETs that is applied to all NETs regardless of their primary site 
in the GI tract, as well as a TNM classification for each site. All NETs are 
considered malignant with the potential to metastasize, although the 
potential differs a great deal between individual tumors and sites. The 
diagnostic criteria for grading of GEP-NETs are in Table 1 and the TNM 
classification for rectal NETs in Table 2. 
 This grading is based on mitotic count and proliferation index by 
Ki-67 immunostaining. In cases of discrepancy between the two parameters, 
the higher grade is to be assumed.  Compared to previous classifications, 
major differences appear.  All tumors are potentially malignant, and, grading 
and TNM classification was introduced. Tumor size or depth of infiltration 
does not affect grade, but are considered in the TNM classification. Use of the 
term “carcinoid” is to be avoided, with the exception of carcinoid syndrome 
and goblet-cell carcinoid. 
 The prognostic accuracy of the WHO 2010 classification has 
been appropriately validated in NETs of the stomach and pancreas, but in the 
rectum, its prognostic value should be confirmed. It is also of interest, 
whether the new WHO 2010 classification is superior to its predecessor, 
WHO 2000 classification.  
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Table 1.     In the World Health Organization (WHO) 2010 classification for 
gastroenteropancreatic neuroendocrine tumors (GEP-NETs), this grading is applied regardless of 
the primary site of the tumor. All GEP-NETs are considered malignant (Bosman et al. 2010). 
 
 
WHO 2010 
grade 
Ki-67 Mitoses 
/10 HPF 
Tumor 
diameter 
Invasion into  
muscularis 
propria 
Invasion into 
vascular  
structures 
G1 
 
G2 
 
G3 
 
≤ 2% 
 
3-20% 
 
> 20% 
< 2 
 
2-20 
 
> 20 
Not 
included 
Not 
included 
Not  
included 
  
Table 2    TMN-classification of rectal neuroendocrine tumors (Bosman et al. 2010). 
 
TNM classification 
T – Primary tumor 
TX     Primary tumor cannot be assessed 
T0      No evidence of primary tumor 
T1      Tumor invades lamina propria or submucosa and is no grater than 2 cm in size 
             T1a   Tumor less than 1 cm in size 
             T1b   Tumor 1 to 2 cm in size 
T2      Tumor invades muscularis propria or is greater than 2 cm in size 
T3      Tumor invades subserosa, or non-peritonealized perirectal tissue 
T4      Tumor perforates peritoneum or invades other organs 
N – Regional lymph nodes 
NX     Regional lymph nodes cannot be assessed 
N0      No regional lymph node metastasis 
N1      Regional lymph node metastasis 
M – Distant metastasis 
M0     No distant metastasis 
M1     Distant metastasis 
  
 
 
 
 ENETS PROPOSALS AND GUIDELINES 
In 2007 the European neuroendocrine tumor society (ENETS) published a 
proposal for grading and staging of midgut and hindgut neuroendocrine 
tumors (Rindi et al. 2007), acknowledging the possibility of malignant 
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behavior in all NETs.  Grading of GEP-NETs according to that ENETS 
proposal and WHO 2010 are congruent, but in the TNM staging of GEP-
NETs, differences emerge between the two systems in the appendix and 
pancreas.  
 
GASTROENTEROPANCREATIC NEUROENDOCRINE 
TUMORS 
INCIDENCE 
NETs are rare tumors arising from neuroendocrine cells of the GI tract and 
pancreas. Based on the hormones that these cells produce, the cell types thus 
far identified number 15 (Rindi & Kloppel 2004), but with only 8 hormones 
recognized in GEP-NETs, thus far (Kloppel 2011). In pancreatic tumors, 
hormonal activity (insulin, glucagon, somatostatin, pancreatic polypeptide, 
gastrin, or vasoactive intestinal peptide VIP) detected in serum and tissues is 
associated with less aggressive behaviour (Morin et al. 2013). 
  In an analysis of 35 825 NETs, 27% occurred in the lungs, 51% in 
the GI tract, 6% in the pancreas, and 16% at other sites (Yao et al. 2008). In 
an autopsy series from Sweden, 1.22% had a carcinoid tumor, 90% of which 
were considered incidental findings (Berge & Linell 1976). In the USA, the 
incidence in 2008 of all GEP-NETs was 3.26/100 000 in men and 2.62 in 
women (Yao et al. 2008). In a German series, the annual incidence of GEP-
NETs was 2.27/100 000 in men and 2.38/100 000 in women (Scherubl et al. 
2013), and in a Swedish study the incidence of GI-NETs (pancreatic NETs 
not included) was 2.0/100 000 for men and 2.4/100 000 for women 
(Hemminki & Li 2001). In Finland, according to the Finnish Cancer Registry, 
200 to 300 GEP-NETs are diagnosed annually (unpublished data).    
The increase in incidence has been marked: Scherübl and colleagues 
detected, in Germany between 1976 and 2006, an increase in annual 
incidence of GEP-NETs from 0.31 per 100 000 inhabitants up to 2.27 in men, 
and from 0.57 to 2.38 in women.  The greatest absolute increase was in NETs 
of the small bowel, and a relative increase in rectal NETs.  The authors 
speculate that this increase, at least in part, can be attributed to colorectal 
cancer screening by colonoscopy and enhanced availability of radiological 
imaging (Scherubl et al. 2013), leading to detection of small (1cm or less in 
diameter), asymptomatic tumors.   As a consequence, the proportion of small 
tumors has been on the rise (Scherubl 2009, 2011). 
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GENETICS 
High-frequency mutations that would be characteristic of a special NET 
subtype, are as yet unknown. Mutations involving classical promoters and 
oncogenes such as protein 53, retinoblastoma, and Kirsten rat sarcoma viral 
oncogene (p53, RB, and KRAS ) that are commonly encountered in many 
solid and epithelial tumors, are absent from NETs.  In epigenetic changes, 
the deoxyribonucleic acid (DNA) sequence itself remains unaltered. Instead, 
gene expression is influenced by heritable changes that include DNA 
methylation, histone modification, and the expression of microribonucleic 
acid (miRNA). These features have been reported in NETs, particularly in 
pancreatic NETs, which have attracted the most attention among GI-NETs in 
terms of genetic studies (Karpathakis, Dibra & Thirlwell 2013). 
 In pancreatic NETs, DNA methylation has emerged in many 
genes such as Ras association domain-containing protein 1, cyclin-dependant 
kinase 2A (RASSF1 and CDKN2A), the latter may even be of prognostic value 
(House et al. 2003). Alterations in chromatin remodelers (histone proteins) 
are common in pancreatic NETs and involve multiple endocrine neoplasia 1, 
death-domain associated protein, and   alpha thalassemia/mental 
retardation syndrome X-linked protein (MEN1, DAXX, and ATRX) (Jiao et 
al. 2011). A distinctive microRNA expression pattern of possible prognostic 
value was detectable in pNETs (Roldo et al. 2006). 
 
NEUROENDOCRINE TUMOR SYNDROMES   
Multiple endocrine neoplasia syndrome-type 1 (MEN1) is a rare tumor 
syndrome with a genetic background. Patients with this syndrome develop 
tumors in several organs of the endocrine system: the adrenal and 
parathyroid gland, the pituitary gland, and the diffuse endocrine system of 
the GI tract. These patients are not exceptionally prone to develop rectal 
tumors, however (Yamaguchi et al. 1980, Salmela 2012). In MEN syndromes 
2A and 2B, a neuroendocrine tumor of the GI tract is not a typical feature. 
 In von Hippel-Lindau disease. another tumor syndrome, 
patients develop hemangioblastomas of the central nervous system and 
retina, renal cell carcinomas, phaeochromocytomas, and neuroendocrine 
tumors of the pancreas. Rectal NETs are not, however, commonly associated 
with this rare syndrome (Maher, Neumann & Richard 2011). 
 
INFLAMMATORY BOWEL DISEASE AND NET 
 
Patients with Crohn´s disease are at increased risk for GI-NET.  Crohn’s is a 
chronic inflammatory bowel disease typically with segmental involvement of 
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the GI tract.  Interestingly, NETs were discovered in the areas of the bowel 
that showed no inflammation at the time of diagnosis. West and colleagues 
speculated in their 2007 study that inflammation (by cytokines and other 
mediators) stimulates enteroendocrine cells and thus promotes hyperplasia 
and, eventually, neoplasia, but the observation was based on four patients 
only.  Increased risk for NET in the ileum and other locations (not the rectum 
in particular) is also associated with ulcerative colitis, but authors speculated 
that this may, at least in part, be due to increased medical attention  
(Hemminki et al. 2008). In patients with ulcerative colitis, colorectal NETs 
are uncommon (Nascimbeni et al. 2005, Fu et al. 2008).  Quinn et al. 
reported a patient who had ulcerative colitis and several microcarcinoids in 
the bowel. When colitis subsided as a result of treatment, the tumors 
resolved. The authors in that particular case speculated the role of an 
inflammatory stimulus as the cause of the NETs (Quinn & Platell 2004). 
 
MANEC INCLUDING GOBLET CELL CARCINOID 
Mixed adenoneuroendocrine carcinomas (MANEC) are exceedingly rare 
tumors, ones having both exocrine (adenocarcinoma) and endocrine 
components. The endocrine component is usually of high grade (G3 NET). In 
these tumors, the two separate components are not sharply demarcated, but 
rather intertwined in close juxtaposition. They occur, although infrequently, 
throughout the GI tract (Klimstra et al. 2010). 
 Another peculiar tumor with neuroendocrine features, the goblet 
cell carcinoid, presenting almost exclusively in the appendix, was first 
described by Gagné et al. in 1969. Subbuswamy and colleagues in 1974 
launched the term “goblet cell carcinoid”, which has persisted and is still 
widely used – a term, however, causing discomfort in many authors. 
Morphologically, this tumor consists of small groups of tumor cells that 
include intracellular mucin (resembling goblet cells) and that express 
neuroendocrine markers at least focally. In most cases, the classical goblet 
cell growth pattern is the sole component, but a combined tumor with a 
component resembling conventional NET has been described (Chetty et al. 
2010). What has been under debate is whether this is an unusual subtype of 
neuroendocrine tumor, or a variant of adenocarcinoma that undergoes 
neuroendocrine differentiation (Roy & Chetty 2010). The TNM classification 
of the appendiceal adenocarcinoma, not the neuroendocrine tumor, is 
applied, reflecting the aggressiveness of this neoplasm. Goblet cell carcinoid 
has never been reported in the rectum. 
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RECTAL NETS 
Of all neoplasms in the rectum, rectal NETs comprise less than 1%. Among 
the most common are benign hyperplastic polyps and other serrated lesions. 
Adenomas, with dysplastic changes in the epithelium, are also common. 
Although considered benign, they are potentially precursor lesions for 
adenocarcinoma, which is the most common malignant tumor in the rectum. 
Melanoma, lymphomas, and benign and malignant mesenchymal tumors 
also occur, although rarely, in the rectum. 
Rectal NETs originate from the rectal endocrine cells. These cells are part 
of the diffuse endocrine system and are dispersed throughout the GI tract. 
The rectum harbors mainly serotonin-producing EC-cells, and the L-cells 
that produce GLI and PYY. Somatostatin-producing D-cells are very few in 
number in the colon and rectum (Solcia, Capella & Fiocca 1998). 
 
GENETIC BACKGROUND AND OTHER PREDISPOSING FACTORS 
No high-frequency mutations involving DNA have been discovered in rectal 
NETs, but some epigenetic changes do occur. CpG island methylator 
phenotype (CIMP) positivity is more common in poorly differentiated 
colorectal NECs, and expression of DNMT1 (de novo methyltransferase),  -3A 
and 3B is associated with advanced stage. Promoter methylation of human 
mutL homolog 1, tissue inhibitor of metallopeptidase 3 (CDKN2A, hMLH1, 
and TIMP3) occur exclusively in colorectal NETs (Arnold et al. 2008, La 
Rosa et al. 2012). 
Patients with genetic syndromes such as von Hippel-Lindau syndrome 
(VHL), multiple endocrine neoplasia syndrome-type 1 (MEN1), and 
neurofibromatosis-type 1 (NF1), sometimes develop GI-NETs. However, 
these patients are not particularly prone to rectal NET. In sporadic GEP-
NETs, a number of different genetic changes arise, but none of them specific 
for rectal NET. 
 
INCIDENCE 
According to the SEER 17 (surveillance, epidemiology, and end results; a 
program of the National Cancer Institute, USA) report, of all NETs (including 
NETs in lungs, pancreas and GI tract), in the USA rectal tumors comprise 
18%, and their proportion of GI-NETs is 27% (Yao et al. 2008). In Europe, of 
all NETs, the proportion of rectal NETs is lower, 5 to 14% (Ploeckinger et al. 
2009, Niederle et al. 2010, Garcia-Carbonero et al. 2010).  It is possible that 
small, benign-appearing tumors are incompletely reported, and that true 
numbers would be higher. In a study from Japan, the rectal NETs 
represented 55.7% of GI-NETs (Ito et al. 2010). Such a high proportion may 
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be attributed to meticulous reporting of even small, polypoid, incidentally 
detected lesions, and to frequency of health checks including colonoscopy 
(Ito et al. 2007). Several countries have screening programs for occult blood 
in stool samples in order to find early-stage colorectal carcinomas: 1 to 2 % of 
screened subjects return a positive sample leading to endoscopy, which may 
also raise the incidence of NETs among the screened population (Hardcastle 
et al. 1996). In Finland, 20 to 30 rectal NETs are diagnosed each year, 
according to the Finnish Cancer Registry (unpublished data), but the exact 
incidence is unknown.  
 In patients with rectal NET, the average age at diagnosis is 48 to 
56 years  (Jetmore et al. 1992, Matsui, Iwase & Kitagawa 1993, Modlin, Lye & 
Kidd 2003, Yao et al. 2008, Korse et al. 2013), compared to 70 years for 
adenocarcinoma (Siegel et al. 2012). No significant gender predominance 
exists, but black and Asian populations in the USA are more commonly 
affected (Modlin, Lye & Kidd 2003, Yao et al. 2008).  
Well-differentiated G1/G2-tumors (grade) predominate in the rectum, 
whereas in other parts of the colon, well-differentiated NETs are less 
common than are poorly differentiated G3-NECs (neuroendocrine 
carcinoma) (Anthony et al. 2010, Ito et al. 2010).  Poorly differentiated NECs 
are high-grade tumors with an unfavorable prognosis  and are often 
disseminated at initial presentation (Bernick et al. 2004, Brenner et al. 2004, 
2007). 
 
SYMPTOMS 
Half the patients diagnosed with rectal NET are asymptomatic (Jetmore et al. 
1992). Endoscopy is readily available in many countries enabling early 
diagnosis of small, asymptomatic rectal NETs (Scherubl 2009, 2011). When 
present, symptoms are caused either by the tumor mass of the primary tumor 
or by metastasis, by biogenic substances secreted by the tumor (carcinoid 
syndrome), or by tumor-induced fibrosis.  Symptoms include abdominal 
pain, weight-loss, GI bleeding, diarrhea, discomfort, change in bowel habits, 
and constipation (Jetmore et al. 1992, Shebani et al. 1999).   
At diagnosis, 75 to 85% of rectal NETs are local (Modlin, Lye & Kidd 
2003, Fahy et al. 2007, Yao et al. 2008). In an autopsy series including all 
primary sites, the most frequent sites of metastases were regional lymph 
nodes (89.8%), liver (44.1%), lung (13.6%), peritoneum (13.6%) and pancreas 
(6.8%) (Berge & Linell 1976). Fahy and colleagues in 2007 reported the liver 
to be the most common site of metastases. Symptoms caused by metastatic 
disease include right upper-quadrant abdominal pain, hepatomegaly, 
lethargy, weight loss, symptoms due to carcinomatosis, and bowel 
obstruction due to fibrosis caused by widespread intra-abdominal disease 
(Caplin et al. 2012a).  
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CARCINOID SYNDROME 
Carcinoid syndrome occurs in around 10% of NET patients, and in 48% of 
patients with liver metastases, but in patients with rectal NET, even when 
metastatic, the carcinoid syndrome is rare, since serotonin-producing tumors 
are uncommon at this site (Shebani et al. 1999). 
 Some NETs produce bioactive substances such as serotonin, 
prostaglandins, histamine, and tachykinins in amounts sufficiently high to 
cause carcinoid syndrome. Classical symptoms include cutaneous flushing 
and diarrhea. Cardiac manifestations, bronchospasm, myopathy, artropathy, 
edema, and skin pigmentation occur less frequently (Modlin et al. 2005). 
Of patients with carcinoid syndrome, 20 to 50% develop carcinoid heart 
disease (Pellikka et al. 1993, Bhattacharyya et al. 2008).  Vasoactive 
substances lead to fibrinoid depositions mainly on the tricuspidal valve and 
pulmonary valve on the right side of the heart, followed by regurgitation and 
stenosis of the valves which may eventually progress to right-sided heart 
failure (Bernheim et al. 2007, Palaniswamy, Frishman & Aronow 2012). The 
lungs have the capacity to degrade the vasoactive substances thus protecting 
the left side of the heart and as a consequence, left-sided carcinoid heart 
disease is observable in cases with a bronchial NET or with a metastatic NET 
producing vasoactive peptides in massive amounts that surpass the capacity 
of the lungs, or with a NET patient’s having a patent foramen ovale 
(Gustafsson et al. 2008).  
 
DIAGNOSTICS 
 
Endoscopy 
Many asymptomatic rectal NETs are discovered incidentally at endoscopy. 
They can be polypoid, or frequently submucosal, causing a subtle bulge in the 
mucosa. They may be yellowish or reddish, or have color similar to that of the 
surrounding mucosa. Endoscopic ultrasound is useful in determining tumor 
size, sharpness of the tumor edges, and depth of infiltration (Matsumoto et 
al. 1991, Liu et al. 2013). High-grade tumors may present as large, 
circumscribed, ulcerated, and even obstructing tumors.  
 
Imaging 
In completely removed G1-NETs, further imaging is not considered 
mandatory, whereas  in G2/G3 lesions, scanning of the liver, thorax, and 
pelvis is recommended, with computed tomography (CT) preferable (Figure 
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2). In evaluation of local stage and depth of invasion, magnetic resonance 
imaging (MRI) is accurate. Transabdominal ultrasound (US) can be useful in 
the search for liver metastasis. Metastatic lesions are sometimes available for 
biopsy with ultrasound guidance (Pelage et al. 1999, Burton et al. 2008, 
Taylor et al. 2011, Caplin et al. 2012a).  Positron emission tomography-
computed tomography (PET-CT, Figure 1) is superior to PET and 
somatostatin reseptor scintigraphy (SRS) in planning treatment of 
disseminated NET (Gabriel et al. 2007, Krausz et al. 2011, Ruf et al. 2011). 
Additional, synchronous tumors must be excluded, since multicentric NETs 
have been described in up to 10% even the in absence of NET syndromes, and 
synchronous non-neuroendocrine tumors in up to 22% indicating a thorough 
radiological work-up of NET patients (Shebani et al. 1999). 
 
Laboratory tests 
Neuroendocrine tumors contain chromogranin A (CgA) protein in their 
neurosecretory granules. The plasma CgA level is measurable and reflects 
tumor burden at time of diagnosis.  The plasma content of CgA decreases 
when the tumor diminishes as a result of the treatment. CgA level is often 
increased in relapses, making CgA a useful marker for follow-up (Pirker et al. 
1998b, Ardill, Erikkson 2003b, Kolby et al. 2004b). Increased CgA is 
associated with some non-neuroendocrine tumors, and elevated levels of 
plasma CgA are encountered in chronic inflammatory bowel disease such as 
Crohn´s disease or ulcerative colitis, reflecting the increased activity of 
neuroendocrine cells in these conditions (Tropea et al. 2006, Sciola et al. 
2009). 
 
Histology 
On routine HE sections (haematoxylin-eosin), rectal NETs can be frankly 
polypoid, or be merely slightly elevated from the surrounding mucosa. The 
neoplastic tissue is usually covered by intact mucosa. Tumor tissue is visible 
in the lamina propria of the mucosa, sometimes as solitary islets or grandular 
formations between normal intestinal glands. Accurate histological diagnosis 
is sometimes challenging from small biopsies. In specimens containing the 
entire tumor, it is easier to determine whether infiltration into the 
muscularis propria or angioinvasion has occurred. Four distinctive growth 
patterns are recognizable: glandular, insular, trabecular, and diffuse 
(Pilichowska et al. 1999). Tumor size is assessed from tissue specimens, as 
well as the frequency of mitotic figures and the presence or absence of 
significant cytological atypia. Grading and staging should be according to the 
WHO 2010 criteria, Tables 1 and 2. 
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Immunohistochemistry 
Although in most cases, the morphology of the tumor is suggestive of its 
neuroendocrine nature, this must always be confirmed by 
immunohistochemistry by chromogranin A and synaptophysin; CD56 
(cluster of differentiation 56) is not recommended, as it is considered less 
specific than other neuroendocrine markers. The proliferation index is 
determined by Ki-67 (Caplin et al. 2012a). 
 Chromogranin A (CgA) is one of the peptides of the 
chromogranin family characterized in 1966. CgA appears in the secretory 
granules of neurons and neuroendocrine cells (Ferrari et al. 1999). Its 
function of is not yet entirely discovered; it may act as a precursor peptide for 
various hormones (Louthan 2011).  Most NETs are positive for CgA by 
immunohistochemistry. Poorly differentiated NECs may be only weakly 
positive, or even negative for CgA (Bussolati, Volante & Papotti 2001, Lloyd 
2003, Arnold et al. 2009). CgA level in serum can be measured and can serve 
as a tumor marker: if a neuroendocrine tumor is clinically suspected, a high 
concentration of CgA in serum corroborates this.  If the level of CgA is 
elevated at diagnosis, it may reflect tumor burden. During follow-up, 
elevated CgA levels can be a sign of tumor recurrence or metastasis (Pirker et 
al. 1998a, Ardill & Erikkson 2003a, Kolby et al. 2004a). 
Synaptophysin, characterized  in 1985, is a protein found in the 
membrane of the small synaptic vesicles (Wiedenmann & Franke 1985) 
occurring in neural cells and in neuroendocrine cells. When the vesicles 
release their content, synaptophysin is involved (Valtorta et al. 2004). By 
immunohistochemistry with a monoclonal antibody, the presence of 
synaptophysin-containing vesicles in NET tumor cells was a finding in 1986 
(Wiedenmann et al. 1986).  Almost all NETs express synaptophysin. Poorly 
differentiated tumors are often negative for chromogranin A, but nearly 
always positive for synaptophysin (Bussolati, Volante & Papotti 2001, Lloyd 
2003, Arnold et al. 2009). 
Ki-67 antigen (see below) is recognized by the MIB-1 antibody used in 
routine diagnostics to evaluate the proliferation index. In the diagnosis of a 
NET, determination of the percentage of MIB-1 positive cells is essential and 
tumor grade is based on the mitotic activity and proliferation index by MIB-1. 
 
METASTATIC NET WITH UNKNOWN PRIMARY 
In clinical practice, metastatic lesions are occasionally discovered prior to 
discovery of the primary tumor.  In cases with a metastatic NET, the site of 
the primary tumor is unknown at initial presentation in up to 30% (Morris et 
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al. 2010, Stoyianni, Pentheroudakis & Pavlidis 2011, Balaker et al. 2012).  
With conventional CT, the primary tumor has been detectable in 20% of 
cases compared to 59% with  68Ga-DOTA-NOC (Gallium; 1,4,7,10-
tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid -  Nal3-octreotide) by 
PET/CT and 39% with  111In-Octreoscan (Prasad et al. 2010).  It is notable 
that even with such sophisticated imaging techniques, a significant 
proportion of primary tumors remain occult.  
 If tissue material from a metastasis is available, gene expression 
analysis may provide valuable information in terms of primary tumor site.  
Primaries of the stomach, small intestine, and pancreas have in some series 
had genetic signatures (Capurso et al. 2006, Posorski et al. 2011, Hainsworth 
et al. 2013). Immunohistochemistry is also helpful: positivity of thyroid 
transcription factor (TTF-1) points towards pulmonary, and CDX2 towards 
gastrointestinal and, more specifically, midgut origin (Erickson et al. 2004, 
Jaffee et al. 2006, Lin et al. 2007). No specific marker exists for rectal origin. 
 
TREATMENT 
Surgical or endoscopic removal is the only curative treatment for localized 
rectal NET. Small lesions are often encountered incidentally at endoscopy, 
and in most cases diagnosis is confirmed at histological examination. 
Sometimes lesions are biopsied, allowing more careful planning of the 
surgery. When choosing the appropriate method, tumor size is important 
(Caplin et al. 2012b). 
 
Endoscopic and surgical treatment   
Endoscopic removal is the treatment of choice in G1-NETs of the rectum 
smaller than 1 cm in size and without infiltration of the muscularis propria. 
(Scherubl et al. 2011, Kwaan, Goldberg & Bleday 2008, Onozato et al. 2010). 
If a small tumor invades the muscularis propria, or is of grade G2 to G3, 
transanal excision should be considered. In tumors 1 to 2 cm in diameter 
with no evidence of muscularis propria invasion or lymph node involvement, 
endoscopic removal is recommended for G1 tumors and transanal excision 
for G2 tumors. However, if a 1- to 2-cm G2 tumor has invaded the muscularis 
propria or beyond, anterior resection of the rectum is recommended, and the 
same applies for G3 tumors (Shields et al. 2010). Even in the presence of 
metastatic lesions, surgical treatment of the primary tumor may be beneficial 
by providing alleviation of local symptoms (Pavel et al. 2012a). 
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Surgical and ablative treatment of metastases 
In patients with disseminated NET at any primary location, distant 
metastases occur most commonly in the liver (Berge & Linell 1976). Three 
patterns of liver metastasis are shown in Figure 1: in 20 to 25%, the 
infiltration has a simple pattern (Type A), in which the metastatic lesions are 
within one liver lobe or in two adjacent segments, and if extrahepatic 
metastases are excluded, liver resection is usually available. In the complex 
pattern (Type B, 10 to 15% of cases), mainly one lobe is affected with minor 
lesions in the contralateral lobe (Figure 1).  With this pattern, liver resection 
still may be feasible. In the diffuse Type C pattern (60 to 70% of cases) 
multifocal metastatic tumors cannot be treated surgically (Pavel et al. 2012a). 
In cases with metastatic G3 NEC, liver resection is usually not recommended, 
but in selected cases with only a few metastatic lesions, it may be considered 
as one option. 
 Ablative treatments including radiofrequency ablation (RFA), 
transcatether arterial embolization (TAE), and transcatether arterial 
chemoembolization (TACE), can serve as the sole treatment in metastatic 
disease, or in conjunction with liver resection. With RFA, complete or 
significant local control has been observed for several months in 80% 
(Berber, Flesher & Siperstein 2002). When RFA is combined with liver 
resection, even total removal of metastatic tumor tissue can be achievable 
even in conventionally unresectable cases, but with tumors less than 3 cm in 
diameter best suitable for this treatment option (Pawlik et al. 2003). 
Significant symptom improvement is achievable in a majority of cases 
(Eriksson et al. 2008b). In a more recent study with metastatic NETs of the 
small intestine, however, no difference was detectable in patients treated 
with RFA or liver resection, and non-surgical therapy (Norlen et al. 2013).  
In TAE and TACE peripheral liver arteries are selectively embolized 
causing ischemia in the metastatic tumor tissue, and in TACE, a 
chemotherapeutic agent, usually doxorubicin or streptozotocin, is also 
injected into the tumor tissue (Ruszniewski et al. 1993, Marrache et al. 
2007). By TACE, the 5-year survival rates have been 50 to 83% and by TAE 
40 to 67%, (Vogl et al. 2009). TAE and TACE were of equal effectiveness, but 
with TAE, fewer complications occurred (Fiore et al. 2014) Rather similar 
results have resulted from selective internal radiation therapy (SIRT) 
(Engelman et al. 2014).  In a recent consensus conference, all ablative 
treatments yielded comparable results, and no method was found superior to 
be others (Kennedy et al. 2014). 
 Since histological data from the primary tumor is useful in 
planning the treatment of the metastases, resection of the primary tumor is 
recommended first. A complete resection of liver metastases leads to survival 
rates of 60 to 80% in 5 years (Chamberlain et al. 2000, Sarmiento et al. 
2003, Elias et al. 2003) in contrast to only 30% in patients without complete 
liver resection (Touzios et al. 2005, Kianmanesh et al. 2005) implying, that 
in disseminated cases the liver resection may be more effective than the 
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resection of the primary tumor.  A larger liver resection is usually not 
combined to resection of the primary tumor, and a two-step approach is 
preferable in these cases (Pavel et al. 2012a). 
 
 
 
 
 
 
 
 
 
Figure 1.       Three different patterns of liver metastases are recognized: Type A (A), Type B (B)     
and Type (C).  Metastatic lesion seen in PET/CT (D). (Images with permission of John Wiley and 
Sons). 
Liver transplantation 
A malignant tumor in the liver is only in exceptional cases an indication for 
liver transplantation. Patients with a slowly progressing G1 or G2 NET which 
fails to respond to any other treatment are thought to benefit most. The 
tumor may be hormonally functioning or non-functioning. A candidate 
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patient for liver transplantation should be followed for at least 6 months 
prior to the operation in order to rule out aggressive tumor behavior and 
small extrahepatic metastatic lesions.  The number of patients treated with 
liver transplantation is limited, with no generally applied consensus criteria 
for patient selection (Pavel et al. 2012b). In Finland, only three patients have 
undergone liver transplantation for liver metastasis of GEP-NET: in one of 
these patients the primary tumor was in the rectum (personal 
communication). 
 
Somatostatin analogs and interferon  
 The somatostatin analogs octreotide and lanreotide have antisecretory 
properties and are effective in treatment of symptoms of carcinoid syndrome 
(a rare event in case of rectal NET) (Eriksson et al. 2008a, Modlin et al. 
2010). Interferon may be combined with somatostatin analogs (Oberg 2000, 
Pavel et al. 2006).  These drugs also have a weak antiproliferative effect: 
reduction of metastatic lesions occurs in fewer than 10% of patients (Faiss et 
al. 2003, Welin et al. 2004, Arnold et al. 2005, Modlin et al. 2010). In the 
PROMID study, metastases treated with octreotide LAR were stabilized in 
67% vs. 37% in the placebo group. The progression-free period was 14.3 
months with octreotide LAR, and 6.0 months with placebo (Rinke et al. 
2009). Thus, somatostatin analogs may be useful (with or without 
interferon) in cases of disseminated G1-G2 NET with unresectable liver 
metastases, whereas in G3 tumors this is not recommended (Pavel et al. 
2012b). 
 
Systemic chemotherapy 
In localized rectal G1-G2 tumors, adjuvant chemotherapy is not a 
recommendation (Caplin et al. 2012b).  In metastatic cases, chemotherapy as 
a treatment option is not well established, but may be considered in rapidly 
progressing cases. G3 tumors should be treated with systemic chemotherapy, 
even in the absence of disseminated disease (Pavel et al. 2012a). No 
publications are available on neoadjuvant therapy (chemotherapy and 
radiotherapy) prior to operation in high-grade cases. 
 
PROGNOSIS OF RECTAL NETS 
At discovery, 2 to 8% of cases have distant metastases (Yao et al. 2008, 
Modlin, Lye & Kidd 2003) and 5% regional metastases (Yao et al. 2008). In a 
Japanese study, distant metastases were present in 8%, and regional 
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metastases in 30% (Ito et al. 2010). Due to increased availability of 
endoscopy, rectal NETs are discovered earlier than previously, and the 
prognosis has improved (Scherubl 2009). The 5-year survival in all rectal 
NETs is 75.2 to 88.3% (Modlin, Lye & Kidd 2003), in patients with distant 
metastases, at 15 to 30% (Soga 2005b, Konishi et al. 2007), and in nodal-
positive disease 34% (Konishi et al. 2007). Small tumors (< 1cm) without 
angioinvasion or infiltration to the muscularis propria have a favorable 5-
year prognosis of 98 to 100% (Soga 2005b, Konishi et al. 2007).  Although 
the rectum is anatomically part of the colon, colonic NETs have a poorer 
prognosis than rectal NETs (Murray et al. 2013). The proportion of 
metastatic tumors among all rectal NETs ought to be assessed in additional 
studies. 
 
Proliferation index by Ki-67 and mitotic rate 
When mice were immunized against nuclei of Hodgkin lymphoma cells in 
1983 in Kiel, Germany, the Ki-67 antibody was the result. The original clone 
was in well number 67 in the 96-well plate (Gerdes et al. 1983). The protein 
recognized by this antibody was named after the antibody: Ki-67. The 
polyclonal antibody was replaced by the MIB-1 antibody (molecular 
immunology Borstel 1). 
 The Ki-67 antibody stains proliferative cells in the G1, S, or G2 
phases or in mitosis. It does not stain resting or quiescent cells in the G0 
phase. The nature of the antigen recognized by the Ki-67 antibody was 
revealed in 1991 (Gerdes et al. 1991) and the complete structure reported in 
1993 (Schluter et al. 1993). It serves widely in clinical pathology as a marker 
of a proliferative, dividing cell, as it is non-specific to any cell type, but 
readily stains all types of proliferative cells. Cellular localization and staining 
intensity varies during the cell cycle, with highest intensity during metaphase 
(Starborg et al. 1996). The proliferation index by Ki-67 alone does not 
determine tumor growth, because it is not entirely certain whether every cell 
in the G1, S, or G2  phases is eventually going to divide, and because the 
duration of the intermitotic phase of a cell cycle varies, and other antigens 
involved in the cell cycle need study, as well.  
 The proliferation index may also reflect the effect of 
antineoplastic drugs on a certain tumor cell population; in tumors with a 
high proliferation index, administration of an antineoplastic drug will lead to 
destruction of more tumor cells when compared to a tumor with a low 
proliferation index. The index predicts the prognosis of various tumor types: 
probably the most extensive data on Ki-67 and its prognosis is for breast 
carcinoma, in which the correlation has been confirmed by several large 
studies. Prognostic significance should be separately studied in each tumor 
type, and use of a combination of cell cycle parameters might prove beneficial 
(Scholzen & Gerdes 2000). 
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 Function of the Ki-67 in cell division remained unclear for a long 
time, and only very recently was it clear that Ki-67 is involved in 
perichromosomal compartment coating, which plays a role in nucleolar 
reassembly and organization after completion of mitosis (Booth et al. 2014). 
 Reports on how well the Ki-67 index (WHO 2010 classification) 
correlates with metastatic potential and prognosis of GEP-NETs in general 
and rectal NETs in particular are few. Yamaguchi and colleagues in 2013 
reported on a series of 45 GEP-NETs in which of 29 rectal NETs, 5 were 
either metastatic or recurred. The conclusion followed that for rectal NETs, 
division into G1/G2 NETs based on the Ki-67 cut-point of the WHO 2010 
classification is appropriate. In duodenal NETs, the predictive value of Ki-67 
is not optimal. Another series included 184 NETs, of which 9 were rectal. 
Interobserver reproducibility of determining the Ki-67 index was high.  In 
the whole series, the Ki-67 index correlated with distant metastasis, but not 
with lymph node metastasis. Rectal NETs were not analyzed as a separate 
group (Nadler et al. 2013). A study of 39 pancreatic NETs included 14 
metastatic cases: all disseminated tumors had Ki-67 index of al least 5% 
(Jorda et al. 2003).   
Rectal NETs with a low mitotic rate (<2/50 HPF) are metastasized in 3%, 
compared to  tumors with an elevated mitotic rate which at least 65% 
metastasize (≥2/ 50 HPF) (Fahy et al. 2007).  
 
Size 
Tumor size of rectal NETs is associated with prognosis. Tumors larger than 2 
cm showed regional metastasis in 58 to 59% and distant metastases in 24 to 
27%, whereas small tumors (1 cm or less in diameter) metastasized to 
regional lymph nodes in 7 to 8%, and never to distant sites (Konishi et al. 
2007, Shields et al. 2010). In two studies that did not separate regional and 
distant metastases, large tumors (>2 cm) were disseminated in 57 to 64%, 
whereas of small tumors (1 cm or less in diameter) 3 to 10% had metastasized 
(Soga 2005b, Fahy et al. 2007). 
 
Angioinvasion  
When lymphatic invasion occurred in the primary tumor, lymph node 
metastases were detectable in 70%, compared to 4% with no lymphatic 
invasion.  As to venous invasion, 73% of positive tumors and 4% of negative 
tumors had metastasized to lymph nodes. Distant metastases occurred in 
31% of positive cases and 3% of negative (Konishi et al. 2007). In another 
study, tumors with lymphovascular invasion metastasized to regional lymph 
nodes in 65% and to distant sites in 17%, compared to 5% and 0% in cases 
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without lymphovascular invasion, but lymphatic and venous invasion were 
not separated (Shields et al. 2010). 
 
Depth of invasion   
Tumors that invade the muscularis propria or beyond have metastasized to 
regional lymph nodes in 43 to 67% and to distant sites in 14 to 29%, whereas 
tumors restricted to the mucosa and submucosa have metastasized to 
regional lymph nodes in 13 to 16%, and to distant sites in 0 to 1% (Konishi et 
al. 2007, Shields et al. 2010). In a study not separating regional and distant 
metastases, of tumors restricted to the mucosa and submucosa 3% had 
metastasized compared to 56% of tumors invading the muscularis propria 
(Fahy et al. 2007). Depth of invasion correlated with prognosis: 5-year 
survival rate for patients without muscularis propria invasion was 100% as 
opposed to 57% in patients with invasion (Wang et al. 2011).  
 
Age 
Older patients (>55 years) had regional lymph node metastases at the rate of 
40%, but younger patients (≤55 years) at only in 20%. Distant metastases 
occurred in 12% in the older age group compared to only 2% in younger 
patients (Konishi et al. 2007). According to Shields and colleagues (2010) the 
metastatic potential of tumors shows no association with age. 
 
FOLLOW-UP 
 
Local tumors 
In small (<1 cm) G1-G2 NETs without lymph node involvement or invasion 
to the muscularis propria, regular follow-up is not considered necessary.  For 
G3 tumors smaller than 2 cm, and G1-G2 NETs of 1 to 2 cm, annual follow-up 
is recommended, notably by endoscopy. Large G1-G3 tumors (> 2 cm) are 
followed by endoscopy, and liver scanning (preferably with MRI or CT), as 
well as by serum markers (e.g. chromogranin A); G1-G2 tumors annually and 
G3 tumors every 4 to 6 months the first year and then annually (Caplin et al. 
2012a).  Local recurrence is rare. The role of repeated colonoscopy as the 
mode of follow-up is questionable (Sauven et al. 1990). 
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Disseminated tumors 
R0/R1 resected liver metastases of G1-G2 NETs are followed by serum 
markers (CgA and/or NSE) and imaging every 3 to 6 months, and G3 NECs 
every 2 to 3 months, and unresectable liver metastases at 3-month intervals 
at first, and at 6- to 12-month intervals in cases of stable disease. SRI should 
be performed after 18 to 24 months or even earlier, if serum markers are 
elevated and conventional imaging shows no enlargement in metastatic 
tumors. If metastases progress rapidly, the proliferation index should be 
evaluated, and biopsy is indicated (Pavel et al. 2012a). 
 
NET patients with second malignancies 
The risk of developing second malignancies is increased: 16.7% of NET 
patients had another malignant tumor either synchronously or 
metachronously (Scherubl et al. 2013). Patients without a second malignancy 
had better prognosis. Common sites of second malignant tumor include: the 
GI tract, female and male genital organs, skin, and breast (Scherubl et al. 
2013). As a consequence in the follow-up, risk of other neoplasms must be 
considered. 
 
TUMOR MARKERS OF THIS STUDY    
Tumor markers are not very extensively studied in neuroendocrine 
neoplasms. The literature has reports on tumor markers mostly in lung 
carcinoids and in pancreatic NETs, but few reports on markers in the GI-
NETs  (see Table 3). The search was performed in Pubmed with the 
keywords: rectum/rectal, neuroendocrine tumor/carcinoid, 
immunohistochemistry, tumor marker and prognosis. Thus, markers should 
be studied in rectal NETs, as studies are, to the best of knowledge, non-
existent. Below are presented in detail the markers that were chosen for 
publications due to their significant correlation with metastatic potential and 
prognosis.  
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Table 3. Tumor markers studied in neuroendocrine tumors of the GI-tract and the lung. 
 
 
 
 
 
Marker Localization/tumor type Result Reference 
p21 GI-NET Over expression = 
poor prognosis 
(Kawahara et al. 
2002) 
E-Cadherin GI-NET Reduced expression 
= poor prognosis 
(Kawahara et al. 
2002) 
p53, cyclin D1, 
Rb, bcl-2 
GI-NET No correlation with 
prognosis 
(Kawahara et al. 
2002) 
E-Cadherin Goblet cell carcinoid of 
appendix 
No correlation with 
prognosis 
(Li et al. 2002) 
Fascin Lung carcinoid High expression = 
poor prognosis 
(Pelosi et al. 2003) 
Beta-catenin Lung carcinoid Altered expression = 
poor prognosis 
(Pelosi et al. 2005) 
COX-2 Midgut NET Over expression = 
poor prognosis 
(Cadden et al. 
2007) 
p53 Gastric NET High expression = 
poor prognosis 
(Safatle-Ribeiro et 
al. 2007) 
LKB1 Lung carcinoid Low expression = 
poor prognosis 
(Amin et al. 2008) 
RUNX1T1 Pancreas NET Under expression = 
poor prognosis 
(Nasir et al. 2011) 
CD44, OTP Lung carcinoid Low expression = 
poor prognosis 
(Swarts et al. 
2013) 
PGP 9.5 Pancreas NET Low expression = 
poor prognosis 
(Tomita 2013) 
 
CDX2, Oct4 Ileum NET No correlation with 
prognosis 
(Heverhagen et al. 
2013) 
IMP3 Lung carcinoid Positivity = poor 
prognosis 
(Del Gobbo et al. 
2014) 
KLF4, p21 Lung carcinoid Lack of expression = 
poor prognosis 
(Naranjo Gomez et 
al. 2014) 
GLP-1 Pancreas NET No correlation with 
prognosis 
(Cases et al. 2014) 
DAXX, ATRX Pancreas NET Negativity = poor 
prognosis 
(Marinoni et al. 
2014) 
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CYCLIN A 
Cyclin A controls the cell cycle by activating the cyclin-dependent kinases 
CDK1 and CDK2. The phosphorylated cyclin A – CDK complex is important 
in the initiation of DNA replication in the S phase.  In the early S-phase the 
amount of cyclin A increases, whereas in mid M-phase it falls. A higher 
amount of cyclin A and a following dysregulation of the cyclin A – CDK 
complex is encountered in several tumors. The exact role of cyclin A in 
mitosis is not completely explained. It may stabilize and prevent the 
degradation of other cyclins (Sherr 1996, Yam, Fung & Poon 2002, Obaya & 
Sedivy 2002). 
 Cyclin A correlates with poor prognosis in gastric adenocarcinoma 
(Mrena et al. 2006). It also correlates with prognosis in squamous cell 
carcinoma of the esophagus and in adenocarcinomas of the endometrium 
and breast (Furihata et al. 1996, Kyushima et al. 2002, Bostrom et al. 2009, 
Santala et al. 2014). High cyclin A level is a predictor of complete response to 
therapy in acute leukemia (Dzietczenia et al. 2011). In neuroendocrine 
carcinoma of the skin (Merkel cell carcinoma), pituitary adenoma, or in non-
small cell lung carcinoma, cyclin A expression has no prognostic significance 
(Turner et al. 2000, Koljonen et al. 2004, Cooper et al. 2009). 
 
PROX1 
The embryonic development of various organs such as the liver, retina, 
lymphatic endothelium, and lens is controlled by a homeobox transcription 
factor encoded by PROX1 (Oliver et al. 1993, Sosa-Pineda, Wigle & Oliver 
2000, Dyer et al. 2003). In the APC mouse model, PROX1 has been 
implicated in the development and progression of intestinal adenocarcinoma 
(Petrova et al. 2008). The protein product of the adenomatous polyposis 
gene, APC, associates with a protein complex containing cytoplasmic beta-
catenin, and degradation is induced in normal cells. Inhibition by Wnt 
signalling leads to accumulation of beta-catenin in the nucleus as a beta-
catenin/TCF (T-cell factor) complex that has the capacity to control the 
expression of numerous genes. PROX1 is upregulated during colorectal 
cancer development, being a target of the beta-catenin/TCF pathway. PROX1 
modulates cell adhesion and extracellular matrix interactions when normal 
intestinal mucosa transforms into an adenoma and invasive carcinoma 
(Petrova et al. 2008, Kinzler, Vogelstein 1996). In non-neoplastic mucosa, 
neuroendocrine epithelial cells and lymphatic endothelial cells express 
PROX1 (Skog et al. 2011). At least 15 types of neuroendocrine cells have been 
identified in the gastrointestinal tract, and PROX1 is expressed in only some 
of them. (Petrova et al. 2008). PROX1 predicts an aggressive clinical course 
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in colorectal adenocarcinoma, and Kaposiform hemangioendothelioma. 
Gliomas are found to express PROX1 (Elsir et al. 2011, Skog et al. 2011, 
Miettinen, Wang 2012).  
 
HES77 
In recent years, a new generation of antibodies, stem cell markers, have 
attracted attention in tumor pathology. The monoclonal, stem cell-associated 
antibody HES77 (human embryonic stem-cell factor 77) was produced by 
immunization of mice against the undifferentiated human embryonic stem 
cell (hESC) line SA167. The antigen epitope of this antibody remains 
unknown thus far. 
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AIMS OF THE STUDY 
It has long been accepted that some rectal NETs have an aggressive clinical 
course but it has been unclear whether the WHO 2010 classification has 
prognostic significance in rectal NETs. Moreover, tumor markers have not 
been studied in rectal NETs. The detailed aims of this study were: 
 
1. To estimate the incidence of rectal NETs in Finland (I). 
 
2. To evaluate, among rectal NETs, the proportion of metastatic tumors (I). 
 
3. To validate the prognostic value of the WHO 2010 classification in rectal 
NETs and to compare the novel WHO 2010 and previous WHO 2000 
classifications (I). 
 
4. To test new markers for rectal NETs able to reliably identify tumors prone 
to   metastasize (II-IV). 
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MATERIALS AND METHODS 
PATIENTS, CLINICAL DATA, AND ETHICAL ASPECTS 
Patients with a rectal NET were identified from the database (Qpati) of the 
Department of Pathology, Helsinki University Central Hospital (HUCH) 
between 1980 and 2005. Tumors found numbered 73, in patients who were 
28 male and 45 female: the mean age at diagnosis was 54 years. Average 
follow-up was 124 months (23 days to 314 months).  During that period of 
time, 118 rectal NETs were registered in the Finnish Cancer Registry 
representing all cases reported in the Uusimaa region. Among these 73 
patients, metastases had occurred in 10 patients, with tissue material 
available in 6. A number of cases were initially diagnosed in private clinics, 
but it is likely that this series includes all overtly malignant cases, since 
treatment of these cases is centralized in public hospitals. Non-metastasized 
cases diagnosed in private clinics were excluded from this tumor series. 
Clinical and follow-up data came from patient records of Departments of 
Surgery and Oncology, HUCH, and from its pathology laboratory database 
(Qpati) of the Department of Pathology. Survival data came from the Finnish 
Population Register Center, and cause of death from Statistics Finland. Of 
particular interest were age at diagnosis, gender, method of surgery (biopsy, 
polypectomy, mucosal resection, or bowel resection) and follow-up, clinical 
symptoms, and local recurrences. In metastatic cases, the time elapsed from 
primary diagnosis to metastasis and treatment were registered. 
The research procedures were approved by the National Authority for 
Medicolegal Affairs  (predecessor of Valvira) and The Ethics Committee of 
the Helsinki University Hospital.  
 
PREPARATION OF TISSUE MATERIAL 
Archived tissue material was available for 73 rectal NETs. Standard 
procedure in diagnostic histopathology has been fixation in formalin 
(aqueous solution containing 37% formaldehyde). The material is washed 
and dehydrated in an ascending alcohol series and treated with an organic 
solvent. The hardened tissue is subsequently embedded in paraffin. From 
archived paraffin blocks, thin slices are cut, paraffin is removed with a 
solvent, and the tissue is rehydrated in descending alcohol series.  
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RE-ANALYSIS OF TUMORS 
All tumor samples were re-evaluated from HE slides by two pathologists 
(Juha Jernman and Johanna Arola) in order to confirm the diagnosis and to 
estimate whether the material was sufficient for immunohistochemistry, with 
tumor size, growth pattern (insular, trabecular, glandular, or diffuse), depth 
of infiltration, mitotic frequency, and vascular invasion recorded.  
 
WHO 2010 CLASSIFICATION 
Tumors were re-classified according to the WHO 2010 classification for 
neuroendocrine tumors of the GI tract. GI-NETs usually exhibit typical, 
recognizable morphology: tumor cells have moderate amounts of cytoplasm 
and a round nucleus with coarse chromatin. Variation in nuclear size and 
shape is seldom considerable. Differing growth patterns are observable, and 
one tumor may show a combination of growth patterns. The neuroendocrine 
nature was confirmed by immunohistochemistry and grade determined by 
proliferation index (Ki-67) and mitotic frequency (Table 1); TNM status was 
determined as shown in Table 2. 
 
TUMOR SIZE AND OTHER FEATURES 
Tumor size was measured on a microscope slide. Larger tumors were 
measured with a ruler and smaller ones in the microscope field. The 
predominant growth pattern was registered for each tumor: insular, 
trabecular, glandular, or diffuse (Kloppel 2004). Some tumors showed a 
combination of growth patterns.  The tumor tissue may be limited to the 
lamina propria, but it may extend to the submucosa and the muscularis 
propria. It may perforate the peritoneum or invade adjacent tissue. Invasion 
into the muscularis propria was classified as invasive growth. Mitotic figures 
were registered per 10 high power fields and invasion of tumor cells into 
vascular spaces. Endothelial marker CD31 served to highlight the vascular 
structures. 
 
IMMUNOHISTOCHEMISTRY AND ANTIBODIES 
In routine pathology, immunohistochemistry is a common method to 
demonstrate the presence of specific antigen in tissues. When tissue material 
is fixed using formalin, cross-linking of protein amino acids prevents tissue 
from deterioration, also masking antigen epitopes, and antigen retrieval is 
needed to expose the immunogenic molecules. This purpose required use of 
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trishydroxymethylaminomethanehydrochloride (tris-HCl), or citrate buffer, 
depending on the antibody, for 20 min at 98°C. Since many tissues and cells 
show endogenous peroxidase activity that may react with the substrate, 
leading to non-specific background staining and making interpretation 
difficult, a peroxidase-blocking solution was necessary. In order to obtain a 
recognizable staining pattern, the choice was EnVision detection system by 
Dako. Slides were counterstained with Meyer’s hematoxylin, enabling 
identification of tissue anatomic structures. 
 Monoclonal antibodies have high affinity for a specific antigen 
epitope. They are produced by the hybridoma technique, in which mice are 
immunized against the chosen antigen. The most specific cell line is then 
selected and fused with a myeloma cell line. Polyclonal antibody raised in a 
laboratory animal is able to detect different epitopes of the antigen and is, in 
that sense, more sensitive but less specific. As many tumors included in the 
series were very small, tumor markers were first underwent study in a test 
series of 18 larger tumors (1 G3, 7 G2 and 10 G1 tumors). With positive 
staining result and possible correlation with metastatic potential, the staining 
was subsequently carried out on the entire series: these antibodies are shown 
in Table 4.  Several antibodies that either showed no immunoreactivity at all 
nor had any correlation with metastatic potential or overall survival were 
tested in the limited series only. These antibodies are listed in Table 5.  
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Table 4.      Antibodies reported in a publication or that qualified for the full series of 
73 tumors. 
 
Antibody Clone Study/ 
Why 
discarded 
Manu- 
facturer 
Dilution Antibody 
type 
Ki-67 Mib-1 I Dako 1:100 Mouse 
mAb 
Chromogranin 
A 
5H7 I Novocastra 1:2000 Mouse 
mAb 
CD31 JC70A I Dako 1:20 Mouse 
mAb 
Pancreatic  
polypeptide 
 I NeoMarkers 1:600 Rabbit 
mAb 
CDX-2 EPR2764Y I CellMarque Ready- 
to-use 
Rabbit 
mAb 
Serotonin 5HT-H209 I Dako 1:10 Mouse 
mAb 
Cyclin A 6E6 II Novocastra 1:50 Mouse 
mAb 
PROX1  III R&D 
Systems 
1:2000 Goat 
pAb 
HES77  IV Fujirebio 1:150 Mouse 
mAb 
MMP9  No 
correlation 
Maerck 1:1000 Rabbit 
mAb 
MMP7 141-7B2 No 
correlation 
Chemicon 1:1500 Mouse 
mAb 
Cyclin D1 SP4 No 
correlation 
NeoMarkers 1:20 Rabbit 
mAb 
VeGF-R3  No 
correlation 
SantaCruz 1:1500 Rabbit 
pAb 
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Table 5.        Antibodies stained on the test series only. All with no correlation except for negative 
staining for Bcl-2 and p53. 
 
Antibody Clone Manu- 
facturer 
Dilution Antibody 
type 
Bcl-2 124 Dako 1:40 Mouse mAb 
MMP2 17B11 Novocastra 1:75 Mouse mAb 
MMP8  Neomarkers 1:200 Rabbit pAb 
MMP25  Sigma-Aldrich 1:300 Rabbit pAb 
GATA3  SantaCruz 1:100 Goat pAb 
GATA4  SantaCruz 1:100 Goat pAb 
GATA6  SantaCruz 1:100 Rabbit pAb 
VeGF-C  Zymed 1:100 Rabbit pAb 
Cip2A  Novus 1:500 Rabbit pAb 
p53 DO-7 Dako 1:1500 Mouse mAb 
p27 Kip1 BD Biosciences 1:100 Mouse mAb 
Hur3A2 3A2 SantaCruz 1:1500 Mouse mAb 
Hur19f12 19f12 SantaCruz 1:30000 Mouse mAb 
COX-2 CX229 Cayman   Chemical 1:100 Mouse mAb 
Endostatin 91318 R&D System 1:75 Mouse mAb 
c-myc 9E10 SantaCruz 1:400 Mouse mAb 
HES5  Fujirebio 1:300 Mouse mAb 
SNAIL  Abcam 1:2000 Rabbit pAb 
BMI-1 1.T.21 Abcam 1:400 Mouse mAb 
EVALUATION OF IMMUNOHISTOCHEMICAL STAININGS 
In all tumors, whole sections were independently analyzed by two 
pathologists blinded to the clinicopathological data. Any cases with 
disagreement required a consensus score. Staining intensity - interpreted as 
a positive result - as well as the localization of the positive staining varied 
between antibodies. 
 
STATISTICAL ANALYSIS 
Correlations between individual clinicopathological characteristics and 
immunohistochemical staining results were assessed with univariate 
analyses, the chi-square test, and Fischer’s exact test. Kaplan-Meier life 
tables were computed by the log-rank test. Survival time was calculated 
starting from the primary diagnosis; follow-up ended either at the last 
follow-up date (or at death from cause other than metastatic NET) or at 
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occurrence of metastasis (disease-free survival), or death from the disease 
(disease-specific survival). Variables emerging from univariate analysis as 
having a significant correlation were tested in Cox regression analysis to 
assess whether a variable would qualify as an independent prognostic factor. 
P-values less than 0.05 were considered statistically significant. 
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RESULTS 
RE-CLASSIFICATION OF TUMORS AND FOLLOW-UP 
Each of the 73 tumors’ neuroendocrine nature was confirmed by positivity 
for chromogranin A. According to the WHO 2010 classification, 61 tumors 
were classified as G1, 11 as G2, and one as G3 (Figure 2). In this study, the 
classification was based on the Ki-67 index, as mitoses were too few to fulfill 
G2 or G3 criteria in any tumor. Of the 61 G1 tumors, none had metastasized 
during follow-up (Table 6), but 3 recurred locally. 
 
Figure 2. In the Uusimaa province of Finland, 118 rectal neuroendocrine tumors 
were diagnosed according to Cancer registry, and 73 of these were included in the 
study. Distribution of grades is shown here. 
 
 
 
 
The 11 G2 tumors were considerably larger than the G1 tumors; 2 of the 
patients (18%) were male, 9 (82%) were female (Table 7). The metastatic rate 
for G2 tumors was high, with nine (82%) patients having metastatic disease. 
Metastatic lesions were detected at initial presentation in three patients, and 
six developed metastases during a follow-up of 4 to 151 months after primary 
diagnosis. Five patients with a G2 tumor died of metastatic rectal NET, and 
??
???
???
???
???
????
????
????
???????? ??? ??? ???
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at the end of the follow-up, four patients with disseminated disease were still 
alive. 
This series included only one G3 patient with distant metastases (liver) at 
initial presentation. According to her records, the tumor was “large,” but its 
exact diameter went  unreported. Only small biopsies were available for 
histology, making it impossible to assess tumor size. Growth pattern was 
diffuse with a proliferation index of 25%. This patient died of metastatic NET 
22 months after diagnosis.  
In the chi-square test, the WHO 2010 grade, tumor size, vascular 
invasion, and muscularis propria invasion correlated with metastatic 
potential. In the Kaplan-Meier life-tables and the log-rank test, the WHO 
2010 grade was a clear prognostic factor. When the distant metastasis was 
the end-point, tumor diameter, muscularis propria invasion, and 
angioinvasion also correlated with prognosis. In Cox multivariate analysis, 
WHO 2010 classification emerged as an independent prognostic factor. 
 
Table 6.      Comparison of present and previous WHO classifications for GI-NETs. Both 
classifications have high correlation with metastatic potential, but in WHO 2000 classification, two 
G1 tumors turned out metastatic, whereas in WHO 2010, all G1 tumors remained local. Both 
classifications with high p-values (p<0.001). 
 
 
  
Metastatic 
disease 
 
 
Local 
disease 
 
WHO 2010 
Grade 
 
 G1 
 
 G2 
 
 
 
 
 
0 
 
9 
 
 
 
 
61 
 
2 
 
WHO 2000 
 
G1 
 
G1b 
 
G2 
 
 
 
 
2 
 
2 
 
5 
 
 
 
63 
 
0 
 
0 
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Table 7.     Some clinicopathological characteristics of the tumor series. Female gender was 
over-represented in the G2-group, and G2-tumors were considerably larger than G1 tumors. 
 
 
 
 
WHO 2010 
Grade 
 
 
Number of 
patients 
 
Gender: 
males 
females 
 
Tumor size 
(mm): 
mean size 
range 
median 
 
 
G1 
 
 
61 
 
 
26 (43%) 
35 (57%) 
 
 
3.6 
1 – 9 
3 
 
 
G2 
 
 
11 
 
2 (18%) 
9 (82%) 
 
 
19 
4 – 40 
17 
 
 
G3 
 
 
1 
 
1 (100%) 
0 (0%) 
 
 
Tumor size 
not available 
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Figure 3.   Islets of tumor cells of a G1 NET are visible in the lamina propria (A) and 
positive staining for chromogranin A confirms the neuroendocrine nature of the 
tumor (B). Trabecular (C) and glandular (D) growth pattern in a G2 NET. Strong 
positive staining result for PROX1 in a G2 NET with diffuse and insular growth 
patterns (E). HES77 is strongly positive in a G2 NET. 
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SIZE AND INVASION INTO MUSCLE WALL AND 
VASCULAR STRUCTURES 
Most tumors were less than 1 cm in diameter; of 63 tumors, only one G2 
tumor was metastatic. Of 1- to 2-cm tumors, four of five were metastatic, and 
the five large tumors were all disseminated. Size showed strong correlation 
with metastatic potential.  
Four tumors had invaded the muscularis propria, all of them metastatic. 
In 69 tumors, no invasion into the muscularis propria was evident, but 
metastases were detectable in 6 patients. Invasion correlated strongly with 
metastatic potential at p<0.001 in the chi-square test.  
Tumor tissue invaded vascular structures in four cases, all metastatic; in 
69 tumors, there appeared no histological evidence of angioanvasion. 
Angioinvasion correlated with metastatic potential at p<0.001 in the chi-
square test. 
 It is of note that especially smaller tumors were often – in 48 
cases -  removed in pieces, often making it difficult to exclude invasive 
growth and to determine exact size. However, in only three G2-G3 tumors 
was this was the surgical method. 
 
TUMORS MARKERS BY IMMUNOHISTOCHEMISTRY 
CYCLIN A 
In this series, 44 tumors were immunohistochemically positive for cyclin A, 
whereas 27  were negative with no expression detectable. Positivity of 0 to 
2% of tumor cells was regarded as of low expression and 5% or more as of 
high expression. None of the tumors showed intermediate expression of 3 to 
4%. All tumors with high cyclin A positivity were metastatic (Table 8). 
Tumors with cyclin A positivity of 1% or less had remained local.  
 Cyclin A expression strongly correlated with WHO 2010 
classification.  Tumor size correlated with cyclin A positivity, but neither age 
nor gender did. High expression of cyclin A correlated strongly with 
metastatic potential. In Cox regression analysis, both WHO 2010 and cyclin 
A were independent prognostic factors, but the WHO 2010 classification was 
stronger than the cyclin A expression. 
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Table 8. Correlation of cyclin A positivity with metastasis, grade, and size. 
 
 
 
Cyclin A 
expression 
n metastasis G1 G2-G3 Size, average  
(range) 
 
Low 
0-2% 
 
 
65 
 
4 (6%) 
 
59 
 
6 
 
5 mm,  
(1 – 40 mm) 
 
High 
≥ 5% 
 
 
6 
 
6 (100%) 
 
0 
 
6 
 
19 mm 
(1 – 30 mm) 
 
 
PROX1 
Normal mucosa showed PROX1-positive neuroendocrine cells. Most 
epithelial cells were negative for PROX1, although some cells in mucosal 
crypts showed positivity for PROX1. Nuclei of endothelial cells in lymphatic 
veins were positive, but nuclei of blood vessel endothelial cells were negative 
for PROX1. Tumors with strong nuclear positivity of ≤50 were classified as 
low expression, and tumors with (positivity of) >50% as high expression. 
Immunohistochemical expression of PROX1 correlated with disease-free and 
disease-specific survival at p<0.001 in chi-square and log-rank tests (Table 
9).  
 
Table 9. Correlation of PROX1-expression with metastatic potential and grade. 
 
PROX1 
 
 
Number 
 
Metastasis  
 
G1 
 
G2 - G3 
 
 
Low 
expression 
 
 
59 
 
4 (7%) 
 
55 
 
4 
 
 
 
High 
expression 
 
 
13 
 
6 (46%) 
 
5 
 
8 
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HES77, CDX2, SEROTONIN AND PANCREATIC POLYPEPTIDE 
The novel stem cell-associated marker HES77 showed significant correlation 
with metastatic potential and prognosis of rectal NETs at p<0.001 in chi-
square and log-rank tests, when tumors were divided into two categories: 
tumors positive and tumors negative for HES77. Its decreased expression in 
metastasis, when compared to that in the primary tumor, predicted poor 
outcome, but the number of cases was too small for statistical analyses. 
CDX2 is a transcription marker expressed by epithelial cells of 
the GI tract and commonly serves as a marker of intestinal origin in tumor 
pathology.  Only two tumors were positive for CDX2: both were G2 tumors: 
one was metastatic, and the other remained local. Five tumors were positive 
for serotonin with no association with metastatic potential. 
 Pancreatic polypeptide was detectable immunohistochemically 
in 24 local tumors and in one disseminated G2 tumor. In statistical analysis, 
neither CDX2, serotonin, nor pancreatic polypeptide had value as prognostic 
marker. 
 57 
DISCUSSION 
 
A subset of rectal NETs have been known to behave in an aggressive manner, 
but predicting this malignant potential has been difficult, with the occurrence 
of metastatic lesions often being the first sign of malignant behavior. In the 
WHO 2010 classification, all GI-NETs are considered malignant, and their 
grading system showed itself, in this study, to be of excellent prognostic 
value.  
 
AGE AND GENDER DISTRIBUTION IN PATIENTS  
Female patients predominated, at 62 of 73. Of patients with a high-grade 
tumor (G2-G3), of 12, 10 were female (83%).  Such striking female over-
representation is a novel finding considering earlier gender percentages 
(Modlin, Lye & Kidd 2003, Yao et al. 2008). The number of high-grade 
tumors was quite small: 12, allowing for a possibility for bias. 
The general belief is that women are more concerned about their health 
than are men, which may lead to higher rates of colonoscopies, during which 
many small NETs unlikely to cause symptoms are discovered incidentally 
(Ito et al. 2007). Their greater concern about their health fails, however, as a 
plausible explanation for female predominance for high-grade tumors, since 
metastatic cases would be diagnosed eventually regardless of gender.  
 Mean age at diagnosis was 54. Others have similarly reported a 
mean of 48 to 56 years (Jetmore et al. 1992, Matsui, Iwase & Kitagawa 1993, 
Modlin, Lye & Kidd 2003, Yao et al. 2008). Patients with colorectal 
adenocarcinoma are at diagnosis a mean 70 years old (Siegel et al. 2012); 
that rectal NETs occur younger may imply differences in tumorigenesis, 
although hyperplastic polyps and adenomas are occasionally encountered in 
considerably younger age groups.  
 
TUMOR SIZE AND HISTOPATHOLOGICAL FEATURES 
In this tumor series, G2 tumors were considerably larger than G1 (mean 4 
mm vs. 17 mm), and tumor size correlated with metastatic potential and 
prognosis. Reports state that tumors larger than 2 cm were disseminated in 
24 to 64% of cases. Tumors smaller than 1 cm metastasized at 0 to 10% (Soga 
2005b, Fahy et al. 2007, Konishi et al. 2007, Shields et al. 2010, Weinstock et 
DISCUSSION 
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al. 2013). In the present study, among the 10 metastatic rectal NETs, only 
one tumor was smaller than 1 cm, whereas of large tumors (> 2 cm), all had 
disseminated. What remains unknown is how rectal NETs develop. In 
colorectal adenocarcinoma, the adenoma-carcinoma sequence is established, 
but in NETs, no pre-malignant lesions have as yet been recognized. Small 
tumors have a low proliferation index and very low metastatic potential. If 
high-grade tumors develop de novo, one would expect to see more small 
high-grade tumors, as well. High-grade tumors were histologically 
monotonous with no discernible low-grade areas. 
Depth of invasion correlated here with metastatic potential. All four 
tumors that invaded the muscularis propria had metastasized. Other authors 
have reached similar conclusions: tumors invading the muscularis propria or 
beyond often metastasize: to regional lymph nodes in 43 to 67% and to 
distant sites in 14 to 29%, whereas in tumors restricted to the mucosa and 
submucosa, metastases occur in regional lymph nodes in 13 to 16%, and at 
distant sites in 0 to 1% (Konishi et al. 2007, Shields et al. 2010). In our study, 
six G2 tumors with no detectable invasion into the muscularis propria had 
metastasized. Some of these tumors were exophytic polypoid lesions, some 
removed by polypectomy. It is important to recognize the risk for aggressive 
behavior in some of these tumors, even in the absence of invasion into the 
muscularis propria. In polypoid adenomas of the colon, malignant 
transformation does occur in cases with high-grade dysplasia. Invasive 
glandular structures in the submucosa can be pointed out, the          so-called 
carcinoma in adenoma, with an acknowledged risk for metastasis. Unlike in 
epithelial neoplasms, in polypoid rectal NETs, histologically proven invasion 
into the muscularis propria is not a prerequisite for aggressive metastatic 
disease. 
 All four tumors with angioinvasion were metastatic, but in six 
metastatic cases angioinvasion was undetectable even with CD31 staining of 
vascular structures; indeed angioinvasion must have occurred, metastasis 
being its indirect evidence. In one study, tumors with lymphovascular 
invasion had a high frequency of dissemination, which is in line with our 
findings (Shields et al. 2010). 
 
WHO 2010 CLASSIFICATION  
Tumor grade according to the WHO 2010 classification had excellent 
prognostic accuracy for rectal NETs: none of the G1 tumors had metastasized 
during follow-up, whereas of 11 G2 tumors, 9 had disseminated. Local 
recurrence of three G1-NETs occurred; the primary lesions were removed in 
pieces, not by polypectomy. 
 The WHO 2010 classification considers all GEP-NETs malignant 
with the potential to metastasize, which is a major difference from older 
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classifications. The multi-step journey has been long, from the benign 
carcinoids as described by Oberndorfer to the neuroendocrine neoplasms of 
today that are all thought to be malignant but still have a more favorable 
prognosis than does conventional adenocarcinoma, which has a 5-year 
survival rate of around 60% (Brenner et al. 2012). The 5-year survival rate for 
rectal NET with liver metastasis is only 24%, as opposed to an overall 
survival for all rectal NETs of 88% (Weinstock et al. 2013), justifying efforts 
to identify tumors with the capability to metastasize. 
 In the present study, WHO 2010 grade was based on the 
proliferation index by Ki-67, since mitotic frequency was very low in all 
tumors not fulfilling G2 criteria. Studies on the prognostic value of WHO 
2010 or Ki-67 in GI-NETs according to primary site are limited. Yamaguchi 
and colleagues concluded in their small series (total 29, with 5 metastatic) 
that WHO 2010 grading was of good prognostic value in rectal NETs. Their 
Ki-67 index was higher in metastatic cases, and in their work, the optimal 
cut-off point dividing tumors into G1 and G2 groups was 2.8%.  Nadler and 
colleagues studied 184 neuroendocrine tumors including some pulmonary 
tumors; Ki-67 correlated with distant metastasis, but no rectal NETs were 
subjected to study separately. A Japanese study that included 43 rectal NETs 
revealed an average Ki-67 index of 3.9% in metastatic cases and 1.0% in local 
tumors (Hotta et al. 2006, Nadler et al. 2013, Yamaguchi et al. 2013). In a 
recent systematic review article covering 4,575 patients diagnosed with rectal 
NET, size emerged as a key feature in tumors with metastatic potential. Risk 
factors were size more than 10 mm, atypical surface, high age (> 60 years), 
and muscularis propria, perineural, or lymphovascular invasion. The WHO 
2010 classification system received a brief mention, but tumor grade was 
discussed no further (McDermott et al. 2014).  As a prognostic factor, in a 
study of 141 rectal NETs, tumor grade was only second to tumor stage. That 
study included 10 G2-G3 tumors, and grade was unavailable in as many as 57 
cases (Weinstock et al. 2013). 
 Reports are few on the impact of tumor grade on metastatic 
potential. Results of the present study are congruent with the few existing 
findings suggesting that grade by WHO 2010 classification is a good 
prognostic factor and reliably recognizes tumors with substantial risk for 
aggressive behavior. 
In the light of this study, patients with G1 rectal NET may not need years-
long follow-up: none showed metastases, and only three patients with a G1 
NET had developed a local recurrence, probably due to incomplete removal 
of the primary tumor.  None of the G1 tumors invaded into the muscularis 
propria. Thus, one follow-up endoscopy to exclude local recurrence would 
seem appropriate; G2 tumors, however, are another matter, because in most 
cases they eventually disseminate. After primary diagnosis, metastases can 
occur years later. One endoscopy to exclude local recurrence is adequate, but 
early detection of metastatic lesions is more essential. The WHO 2010 
classification had better prognostic value than the previous WHO 2000 
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classification in rectal NETs. Although WHO 2010 classification is of 
excellent prognostic value, when metastatic propensity is being assessed, 
tumor size remains an important parameter. 
 
TUMOR MARKERS BY IMMUNOHISTOCHEMISTRY 
CYCLIN A AND KI-67 
Cyclin A expression correlated with rectal NETs’ metastatic potential, since 
all tumors with high expression of cyclin A were metastatic (II).  Cyclin A can 
facilitate the differentiation of dysplastic nevi from thin melanoma, and Spitz 
nevi from melanoma (Stefanaki et al. 2007, Kiszner et al. 2014). In 
superficial spreading melanoma, cyclin A is an independent prognostic factor 
(Florenes et al. 2001). Few reports exist concerning cyclin A expression in 
epithelial neoplasms, but in GI-NETs, to the best of knowledge, it has not yet 
been described.  When evaluated in neuroendocrine carcinoma of the skin 
(Merkel cell carcinoma), no correlation with prognosis was detectable 
(Koljonen et al. 2004).  
Ki-67 is a strong marker of prognosis in a plethora of tumor types. It is 
expressed extensively during the cell cycle in dividing, proliferative cells and 
is probably the most widely used and best validated proliferation marker in 
clinical pathology. However, cell-cycle markers need testing separately in 
every tumor type, because duration of each cell-cycle phase varies between 
cell types, and what remains uncertain is whether all cells that have entered 
the cell cycle eventually divide. Additionally, researchers have been 
encouraged to study the prognostic significance of a combination of cell-
cycle-associated markers (Scholzen & Gerdes 2000). We investigated the 
expression of two proliferation markers; G2 tumors with high cyclin A 
expression were all metastatic, contrasting with G2 tumors with low cyclin A 
expression, where 67% were metastatic, so such a combination might prove 
useful in identifying tumors at highest risk for metastasis. These patients 
need the most intensive follow-up to detect metastatic lesions at an early 
stage, and may benefit from adjuvant therapy even without evidence of 
metastatic disease. 
 
PROX1 
Colorectal adenomas and carcinomas harbor tumor stem cells with the ability 
to self-renew and differentiate. They play a role in tumor recurrence, in 
metastasis, and in development of resistance to antiangiogenic drugs. Some 
of these tumor stem cells express PROX1, thus contributing to their tumor 
stem-cell characteristics. Moreover, PROX1 is not involved in maintaining 
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the homeostasis of the normal epithelium, making it an interesting target for 
antineoplastic therapy (Wiener et al. 2014).  
 When adenoma of the colon transforms into invasive carcinoma, 
PROX1 is involved, and its expression correlates with prognosis (Kinzler & 
Vogelstein 1996, Petrova et al. 2008). In gastric cancer, cytoplasmic PROX1- 
positivity correlates with prognosis (Taban et al. 2014). In renal cell 
carcinoma, high PROX1 expression indicates poor prognosis (Lv et al. 2014). 
It has value in differential diagnostics of vascular neoplasms (Le Huu et al. 
2010, Wang et al. 2013).  A subset of enteroendocrine cells express PROX1 
(Petrova et al. 2008), but reports are very few on PROX1 expression in 
neuroendocrine tumors of  the GI tract. In the present study, 
immunohistochemical positivity for PROX1 was demonstrated in a 
significant proportion of rectal NETs, as well as its increased expression in 
metastases. PROX1 correlated with metastatic potential and prognosis, 
although not as strongly as did WHO 2010 grade. These results suggest that 
oncogenesis of rectal NETs and  oncogenesis of colonic adenocarcinoma may, 
at least in part, share the same pathways. Although the prognostic value of  
the WHO 2010 classification exceeds that of PROX1, therapeutic applications 
may emerge in the future (Wiener 2014). 
 
HES77 
Study IV showed that the stem-cell associated marker HES77 was expressed 
in 28% of  rectal NETs. It correlated with metastatic potential and prognosis 
of rectal NETs. This marker is novel: the antibody emerged when mice were 
immunized against a human embryonic stem-cell line. As the exact antigen 
epitope has not yet been revealed, its function and role in the cell remain 
unclear. Reports of HES77 expression are lacking, with only a few reports on 
the expression of other stem-cell markers in neuroendocrine neoplasms. 
Insulin-like growth factor II mRNA-binding protein 3 (IMP3) correlates with 
poor prognosis in the neuroendocrine tumors of the lung (Del Gobbo et al. 
2014). Spalt-like transcription factor 4 (SALL4) and sex-determining region 
Y-box 2 (Sox2) are transcription factors associated with embryonic stem-cell 
pluripotency, immunohistochemical expression has been detected in lung 
small-cell neuroendocrine carcinoma, and Sox2 expression is associated with 
poor prognosis (Sholl, Long & Hornick 2010, Miettinen et al. 2014). In non-
small-cell lung carcinoma with neuroendocrine differentiation, expression of 
the stem-cell markers CD117, CD133 (cluster of differentiation), and ATP-
binding cassette sub-family G member 4 (ABCG4) have had no prognostic 
significance (Gottschling et al. 2013). Positivity of CD117 has been detectable 
with prognostic value in colorectal poorly differentiated NEC and MANEC 
(La Rosa et al. 2012). Few reports cover expression of stem-cell markers in 
neuroendocrine tumors, and most concern lung NETs. 
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 In view of the present study, investigation of expression of other 
stem-cell markers in GI-NETs is encouraged, since it might supply important 
information on GI-NETs, particularly on their tumorigenesis.   
 
STUDY LIMITATIONS 
Neuroendocrine tumors tumors are very rare; approximately 20 to 30 new 
rectal cases occur annually in Finland (personal communication), and 
collecting extensive tumor series with a large number of cases is time-
consuming. During the study period of 25 years, 118 from the Uusimaa 
region were reported to the Cancer Registry, of which 73 were included here. 
All of the overtly malignant, metastatic cases are probably included in the 
series, but it is possible that some non-metastasized G2 tumors are missing 
because systematic classification and grading has been common practice only 
in recent years, raising the proportion of metastatic tumors among G2-NETs. 
And of course, a higher number of tumors might have enhanced the accuracy 
of this study.  
The present study of 73 rectal NETs included merely one G3-NEC, which 
is a weak point; this may in fact be due to pathologists’ imperfect recognition 
of these tumors. If the pathologist is unaware of the entity, G3-NECs can be 
confused with poorly differentiated adenocarcinoma. In cases of poorly 
differentiated tumor without the glandular formations characteristic of 
adenocarcinoma, their morphology should raise suspicion of a poorly 
differentiated neuroendocrine tumor. This should then lead to 
immunohistological staining of neuroendocrine markers. Re-evaluation of 
poorly differentiated adenocarcinomas in order to find more NECs was 
beyond the resources and scope of this study. Besides, a fact already known is 
that poorly differentiated NECs are very aggressive neoplasms with a dismal 
prognosis. Whether any differences existed in metastatic potential and 
prognosis between G1 and G2 tumors was of more interest. 
Diagnostic procedures have evolved since the 1980s, when the tumor 
series started: radiological work-up of patients with a recently diagnosed 
rectal NET was an uncommon practice, since these tumors were then 
considered benign. With current follow-up practices, some metastases might 
have been detected earlier. Follow-up of patients was more or less arbitrary. 
Because guidelines for treatment have existed for only a few years, surgical 
treatment was variable. Many tumors were removed in pieces rather than by 
polypectomy, occasionally resulting in incomplete removal and local 
recurrence. From small, fragmented pieces obtained for histology, it was 
sometimes impossible to reliably confirm or exclude invasion to the 
muscularis propria. As a result, it was impossible to determine the TNM 
status retrospectively, clearly a study shortcoming. 
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Immunohistochemistry as a delicate technique has an in-built possibility 
of false-positive and false-negative staining results for several reasons. We 
had tissue sample from only six metastases (III and IV), and a very specific 
conclusion cannot emerge from such a small number of cases. In the actual 
tumor series, whole tumors and whole sections were analyzed, but of the 
metastases, some of the samples were biopsies and thus represented only a 
small portion of the metastasis. 
A number of markers failed to show a significant correlation, or had no 
correlation at all with the metastatic potential, or were completely negative 
(Tables 4 and 5), and they may not be among the most promising markers of 
neuroendocrine differentiation or prognosis in NETs of other parts of the GI 
tract. Nevertheless, one must bear in mind that NETs of different regions of 
the GI tract must be studied separately, and it is not entirely excluded that 
useful markers will eventually emerge from the group of markers which 
showed no prognostic value in this study. 
Treatment of disseminated rectal NETs has undergone significant 
changes over time. As guidelines have been available only for a short period, 
treatment has followed differing treatment regimens, perhaps affecting 
patient survival.  
FUTURE PROJECTS 
The prognostic accuracy of the WHO classification and proliferation index 
are best validated in NETs of the pancreas. As the same classification is 
applied to all parts of the GI tract, prognostic significance ought to be studied 
in all of them separately. In terms of rectal tumors, it would be interesting to 
re-assess tumors that were diagnosed as poorly differentiated or 
undifferentiated adenocarcinomas, in order to discover how many of them 
are in fact neuroendocrine carcinomas. It would be beneficial to gradually 
expand the tumor series, and to thus enlarge the number of G2 tumors: this 
would allow verification of the proportions of different grades among rectal 
NETs. Follow-up periods should be longer since these tumors often 
metastasize very late. Although the WHO 2010 reliably predicts the 
prognosis of rectal NETs, additional new markers need testing in the quest 
for an even better marker.  
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CONCLUSIONS 
The present studies on rectal NETs allow following conclusions: 
 
 
1) Rectal neuroendocrine tumors are rare with 20 to 30 new cases diagnosed 
in   Finland   annually. 
 
2) Around 10% of rectal NETs will develop metastases eventually. G2-NETs 
of the     rectum have a high metastatic potential. Long follow-up is 
recommended, since neuroendocrine tumors could metastasize even very 
late. Repeated colonoscopies may not be the most effective method of follow-
up; instead, early detection of metastasis should have the highest priority. 
 
 
3) The WHO 2010 classification for rectal NETs has excellent prognostic 
accuracy and is superior to its predecessor, the WHO 2000 classification. 
 
4) All G2-tumors with high cyclin A expression metastasized. HES77 and 
PROX1 correlated with prognosis and PROX1 may be involved in 
oncogenesis of rectal NETs. 
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